The drug trial that led to the death of one participant and brain damage to several others last month had three major shortcomings, according to French health minister Marisol Touraine. First, the drug continued to be tested after the first volunteer became ill. Second, volunteers were not informed of the illness and were not given a chance to withdraw their consent. And, third, no report was made to the proper authorities until the first volunteer had already been hospitalized for four days.
MIA relies on the support of its readers to exist. Please consider a donation to help us provide news, essays, podcasts and continuing education courses that explore alternatives to the current paradigm of psychiatric care. Your tax-deductible donation will help build a community devoted to creating such change.